Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

FDA WOULD RECEIVE $744.1 MIL. IN FY 1993 APPROPRIATIONS UNDER HOUSE BILL

Executive Summary

FDA WOULD RECEIVE $744.1 MIL. IN FY 1993 APPROPRIATIONS UNDER HOUSE BILL that cleared the full appropriations committee on June 25. The House fiscal 1993 budget for FDA represents a 2.5% increase (or $18.2 mil.) over fiscal 1992 agency appropriations and includes no provision for user fees. The committee report notes that the "increase above the fiscal year 1992 amount is to cover salary and benefit costs to maintain personnel at the 1992 level." The Appropriations Committee markup provided the first public glimpse of the House budget for FDA in fiscal 1993. The Appropriations/Agriculture Subcommittee met in closed session on June 10 to mark up the 1993 appropriations bill for agriculture, rural development, FDA and related industries. The subcommittee held a hearing on March 24 on the FDA budget ("The Pink Sheet" March 30, p. 17). On the issue of FDA user fees, the report states: "It is disappointing that the Department of HHS and the Office of Management and Budget continue to gimmick the budget request for FDA by assuming collection of user fees." The report adds that "testimony before the Committee indicates that even if FDA had authority for such fees, it would take 18 to 24 months to develop a program to begin collection." The committee report calls the Administration's "assumption" of FDA user fees in its budget "only a shell to mask budget problems." The Administration had sought fiscal 1993 appropriations for FDA of $557 mil., to be supplemented by $200 mil. in user fee revenues. A draft user fee bill is currently circulating on the Hill ("The Pink Sheet" June 15, p. 3). Speaking at the Appropriations Committee markup of the FY 1993 agriculture appropriations bill, Rep. Skeen (R-N.M.). noted that OMB's analysis of the House agriculture appropriations bill was generally favorable. However, he said OMB was critical of the absence of a provision in the bill for FDA user fees. Skeen pointed out that user fees "do require authorization" and that the committee decided to "go with the rules." The House appropriations bill (HR 5487) does not provide the agency with FY 1993 funding for the proposed FDA campus. The bill provides $8.35 mil. for buildings and facilities -- the same amount included in last year's appropriations. The report contains several committee provisions, including a recommendation apparently directed at inadvertent needle sticks that might spread an AIDS infection. The committee said it "supports efforts by FDA to reduce the hazards to users and patients posed by needlebearing medical devices," and recommended that the agency "consider all needle uses,...take action to remove devices with unnecessary needles from the market and...assure that all remaining needle bearing devices have an effective mechanism to protect the user from needlesticks." In addition, the committee said it "is aware of the need to increase the number of trained biomedical scientific personnel in clinical pharmacology and supports the concept of a pilot training program for clinical pharmacology." However, the report adds: "Due to fiscal constraints placed on the committee, it is unable to provide additional funds for this program."

You may also be interested in...



Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data

Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011

FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance

FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials

Shire Hopes To Sow Future Deals With $50M Venture Fund

Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth

Latest Headlines
See All
UsernamePublicRestriction

Register

PS021103

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel